Artificial Intelligence in Skin Cancer Detection: Is Clinical Deployment Outpacing Experimental Validation?
Experimental Dermatology · 2026-11 · 35 (11)
DOI: 10.1111/exd.70402 ↗At a glance
Journal article in Experimental Dermatology, published online on 2026-11-13. Written by D Reifs and 10 co-authors. Institution: Research Group on Data and Signal Processing, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain. Major MEDLINE topics: Skin Neoplasms, Artificial Intelligence. 63 references.
Abstract (original language)
Deep neural networks classify dermoscopic and clinical images of skin lesions with accuracy that matches, and in curated comparisons exceeds, experienced dermatologists. Regulators have responded: an elastic scattering spectroscopy device with an embedded classifier is authorised for primary care in the United States, an image‐based system has conditional approval in the National Health Service, and consumer applications are marketed directly to the public. In this Viewpoint we argue that clinical deployment is advancing faster than the experimental evidence that investigative dermatology would normally demand. Performance measured on internal test sets falls when algorithms are exposed to external images, non‐dermoscopic photographs or other populations. Networks learn confounders, such as surgical ink markings, as readily as morphology, and the histopathological reference standard is itself subject to substantial observer variation. Public training datasets record skin phototype for about 2% of images and contain almost no darkest‐phototype, acral or nail images. Regulated devices with prospective evidence achieve high sensitivity or negative predictive value at the cost of low specificity, shifting referral and biopsy rates with unmeasured effects on patient outcomes and overdiagnosis, and the single randomised trial to date improved diagnostic accuracy, chiefly among non‐dermatologists, without measuring those outcomes. We identify where the largest gains lie, in primary care, allied health and under‐served regions, and propose an experimental agenda: phototype‐stratified external validation, shortcut‐detection and counterfactual explanation studies, consensus histopathological labelling, pragmatic randomised trials with outcome endpoints reported to CONSORT‐AI, and post‐market surveillance under the European Medical Device Regulation and Artificial Intelligence Act.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Research Group on Data and Signal Processing, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain.
- Digital Care Research Group, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Spain.
- School of Health Sciences, College of Health, Medicine and Wellbeing, the University of Newcastle, Callaghan, New South Wales, Australia.
- Hunter Medical Research Institute (HMRI), Newcastle, New South Wales, Australia.
- School of Psychology, the University of Newcastle, Callaghan, New South Wales, Australia.
- Consorci Hospitalari de Terrassa, Health Consortium Foundation, Terrassa, Spain.
ORCID profiles: D Reifs, L Casanova, F Hawke, A Fellas, E Stevenson, X Girones, S Diez-Alvarez, D Santos, A Coda
Cite
APA
Reifs, D., Casanova, L., Hawke, F., Fellas, A., Eidels, A., Stevenson, E., Croft, E., Girones, X., Diez-Alvarez, S., Santos, D., & Coda, A. (2026). Artificial Intelligence in Skin Cancer Detection: Is Clinical Deployment Outpacing Experimental Validation?. Experimental Dermatology, 35(11). https://doi.org/10.1111/exd.70402
Vancouver
Reifs D, Casanova L, Hawke F, Fellas A, Eidels A, Stevenson E, et al. Artificial Intelligence in Skin Cancer Detection: Is Clinical Deployment Outpacing Experimental Validation?. Experimental Dermatology. 2026;35(11). doi:10.1111/exd.70402
BibTeX
@article{Reifs2026,
author = {Reifs, D and Casanova, L and Hawke, F and Fellas, A and Eidels, A and Stevenson, E and Croft, E and Girones, X and Diez-Alvarez, S and Santos, D and Coda, A},
title = {Artificial Intelligence in Skin Cancer Detection: Is Clinical Deployment Outpacing Experimental Validation?},
journal = {Experimental Dermatology},
year = {2026},
volume = {35},
number = {11},
doi = {10.1111/exd.70402}
}
EUVIMED